Shenzhen Salubris Pharmaceuticals Co., Ltd.
Pharmaceutical industry · Shenzhen, Guangdong
About Shenzhen Salubris Pharmaceuticals Co., Ltd.
Shenzhen Salubris Pharmaceuticals Co., Ltd., known commercially as Salubris, is a pharmaceutical company founded in 1998 and listed on the Shenzhen Stock Exchange (002294). From its headquarters in Futian District, Shenzhen, it integrates research and development, manufacturing and sales of medicines and medical devices, with subsidiaries and production sites in Chengdu, Suzhou, Huizhou, Shandong and Beijing.
Its portfolio focuses on three main areas: cardiovascular and cerebrovascular medicines, where its antiplatelet and hypertension and heart failure therapies hold leading positions in the Chinese market; cephalosporin antibiotics, covering both active ingredients and finished formulations; and bone resorption inhibitors for the treatment of osteoporosis. A cardiovascular medical technology line developed by its specialised subsidiaries complements the drug business.
Salubris pursues a strategy of continuous innovation, with clinical-stage projects in cardiology, metabolism and other areas of high medical need, and a commercial network covering hospitals across China. Its combination of high-volume established medicines and new products in development makes it one of the best-known mid-sized pharmaceutical companies in China.
Its portfolio focuses on three main areas: cardiovascular and cerebrovascular medicines, where its antiplatelet and hypertension and heart failure therapies hold leading positions in the Chinese market; cephalosporin antibiotics, covering both active ingredients and finished formulations; and bone resorption inhibitors for the treatment of osteoporosis. A cardiovascular medical technology line developed by its specialised subsidiaries complements the drug business.
Salubris pursues a strategy of continuous innovation, with clinical-stage projects in cardiology, metabolism and other areas of high medical need, and a commercial network covering hospitals across China. Its combination of high-volume established medicines and new products in development makes it one of the best-known mid-sized pharmaceutical companies in China.